Humanitarian aid
Together with Sanofi, we intend to donate up to 1 billion international units (IU) of factor replacement for use in developing countries.
More than 75 per cent of people with haemophilia around the world have limited or no access to diagnosis and treatment, particularly in the developing world. People with severe haemophilia in these countries often do not survive to adulthood; for those who do, life often entails severe disability, isolation, and chronic pain. The World Federation of Hemophilia (WFH) Humanitarian Aid Program helps address the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. The program has supported 112 countries since its inception in 1996. Read about the progress made by WFH during 2024 in the Humanitarian Aid Impact Report 2024.
WFH's Humanitarian Aid Program provides a more predictable and sustainable supply of medicines, enabling patients to have reliable access to treatment and care. In addition, training programs for care providers and patients are needed to develop the local capacity for better diagnosis and follow up treatment and enable changes that are sustainable in the long term.
In 2020, we announced an extension of our support for the WFH Humanitarian Aid Program with an additional donation of up to 500 million international units (IU) of factor therapy for humanitarian use, fulfilling the 2014 pledge to donate up to an unprecedented 1 billion IU over a 10-year period.
In 2025, we renewed our commitment, signing a new agreement to provide up to 100 million IUs of factor therapy per year for up to five more years. The donated therapy will be distributed by the WFH to people in need in more than 50 countries, helping to ensure continued access to life-changing treatment.
Since the initial pledge in 2014, more than 810 million IU have been donated, and over 22,000 people with haemophilia have been treated with factor donated by Sobi and Sanofi. Both companies are recognised by the WFH as Founding Visionary Partners of this programme. Other contributors include Bayer, CSL Behring, Chugai, Genentech, Roche, Grifols, Takeda, Japan Blood Products Organization, Hemophilia of Georgia.
Read stories about some of the people who have been impacted by the donation.
See more films about the impact here.